Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Euro area Q3 GDP (final) annualized 1.3% vs 1.3% expected; prior reading revised down to 1.2% from 1.30%.
2026-11-13
Euro area Q3 GDP (final) annualized 1.3% vs 1.3% expected; prior reading revised down to 1.2% from 1.30%.
Back
Other News
2026-11-13
Canada's manufacturing backlog rose 2.1% month-on-month in September, compared with 0% in the previous month.
Canada's manufacturing backlog rose 2.1% month-on-month in September, compared with 0% in the previous month.
2026-11-13
Citigroup analysts say Sanofi’s best-selling drug Dupixent could face competition in coming years from AstraZeneca’s tozorakimab, Pfizer’s tilrekimig and AbbVie/Apogee’s zumilokibart. Dupixent (developed with Regeneron) drove Sanofi’s third-quarter b
Citigroup analysts say Sanofi’s best-selling drug Dupixent could face competition in coming years from AstraZeneca’s tozorakimab, Pfizer’s tilrekimig and AbbVie/Apogee’s zumilokibart. Dupixent (developed with Regeneron) drove Sanofi’s third-quarter beat. Citigroup forecasts Dupixent sales growth slowing from an estimated 32% this year to 12% in 2027, and warns Dupixent’s pricing advantage may no longer support growth after 2027. Citigroup raises Sanofi PT to €93 from €78.
Chat with us
, powered by
LiveChat